Product Description: Wegovy (Semaglutide) Weight Loss Injection – USA
Wegovy® (Semaglutide) is a once‑weekly prescription injection approved in the USA for long‑term weight management in adults and adolescents with obesity, or adults who are overweight with weight‑related health problems. It is used alongside a reduced‑calorie diet and increased physical activity, and recent FDA updates (March 2026) include expanded dosing options up to 7.2 mg
What It Is
- Brand Name: Wegovy®
- Generic Name: Semaglutide
- Drug Class: GLP‑1 receptor agonist
- Form: Prefilled, single‑dose pens for subcutaneous injection (under the skin)
- Dosing Schedule: Once weekly self‑administered injection
Available Strengths
- 0.25 mg / 0.5 mL
- 0.5 mg / 0.5 mL
- 1 mg / 0.5 mL
- 1.7 mg / 0.75 mL
- 2.4 mg / 0.75 mL
- New high‑dose option: 7.2 mg (FDA approved March 2026)
Indications
- Weight loss & long‑term weight management in:
- Adults with obesity (BMI ≥30)
- Adults who are overweight (BMI ≥27) with at least one weight‑related condition (e.g., hypertension, type 2 diabetes, high cholesterol)
- Adolescents ≥12 years old with obesity
- Cardiovascular protection: Reduces risk of major adverse CV events (heart attack, stroke, CV death) in adults with obesity/overweight and established cardiovascular disease.
- Liver health: Approved for metabolic dysfunction‑associated steatohepatitis (MASH) in adults with moderate to advanced fibrosis.
How It Works
- Mimics GLP‑1 hormone, regulating appetite and food intake.
- Helps patients feel fuller longer, reducing calorie consumption.
- Clinical trials show average weight loss of ~21% at 72 weeks with the 7.2 mg dose when combined with diet and exercise.
⚠️ Safety & Warnings
- Boxed Warning: Risk of thyroid C‑cell tumors (seen in rodents; human relevance unknown).
- Contraindications:
- Personal/family history of medullary thyroid carcinoma (MTC)
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity to semaglutide or ingredients
- Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain.
- Serious Risks: Pancreatitis, gallbladder disease, kidney injury, low blood sugar (especially with diabetes medications).
📦 Key Selling Points (USA Market)
- FDA‑approved for multiple indications including obesity, CV risk reduction, and MASH.
- Convenient once‑weekly injection with easy‑to‑use pen device.
- Clinically proven weight loss results (up to 21% body weight reduction).
- Expanded dosing options allow personalized treatment.
- Trusted manufacturer: Novo Nordisk.




Reviews
There are no reviews yet.